Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: J Immunother. 2010 Nov-Dec;33(9):965–974. doi: 10.1097/CJI.0b013e3181fb045d

Figure 3. Melanoma cells, but not CD14+ cells, produce CXCL9, CXCL10, and CXCL11 in response to IFN-γ treatment.

Figure 3

A) Staining for S100 and CXCL9, CXCL10, or CXCL11 in melanoma-involved node (MIN) cell suspensions, gated on CD45-CD11c- populations. B) Staining for S100 and CXCL9, CXCL10, or CXCL11 in MIN suspensions gated on CD45+ cells. C) Staining for CD14 and CXCL9, CXCL10, or CXCL11 in tumor-free node (TFN) cell suspensions, gated to exclude dead cells and doublets. D) Staining for CD14 and CXCL9, CXCL10, or CXCL11 in sentinel immunized node (SIN) cell suspensions, gated to exclude dead cells and doublets. Data are representative from one of three similar experiments.